We can’t advance wet AMD research without your help.

About the COAST and ShORe Wet AMD studies

The COAST and ShORe studies will look at whether an investigational medication improves vision for people with neovascular (wet) age-related macular degeneration (AMD), when given with an approved standard medication. The studies will also aim to learn more about the safety of the investigational medication with an approved standard medication. These combinations have already been studied in early phase clinical studies.

• OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (COAST)
• OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

The investigational medication in these studies targets vascular endothelial growth factor (VEGF)-C and VEGF-D, which are critical mediators of blood vessel growth. The hope is that when the investigational medication is combined with a VEGF-A inhibitor, there may be an improvement in vision over and above vision gains achieved with administration of a VEGF-A inhibitor alone.

Who can take part?

Your patient may be eligible to participate in a study if they meet the following criteria:

Inclusion criteria

• Are at least 50 years of age
• Have been diagnosed with wet AMD
• Are experiencing symptoms that may be related to wet AMD, such as problems with central vision loss and blurred vision
• Have not yet received treatment for their wet AMD

Patients must meet all other study criteria to take part in the COAST or ShORe Study.

What to Expect

If the study is right for your patient and they want to take part, the patient:

• Will be in the study for just under 2 years (102 weeks)
• Will visit the study center every 4 weeks
• May receive compensation for time and travel

Get started by registering

Click below to register. It will take about 2–5 minutes. We’ll partner you with a dedicated study representative.